FC
IOVA icon

FORA Capital’s Iovance Biotherapeutics IOVA Stock Holding History

FORA Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,106
Closed -$53.6K – 601
2025
Q1 		$53.6K Buy
+16,106
New +$83.1K 0.01% 479
2021
Q1 		– Sell
-13,314
Closed -$618K – 927
2020
Q4 		$618K Buy
13,314
+12,760
+2,303% +$507K 0.09% 242
2020
Q3 		$18K Buy
+554
New +$17K 0.01% 595
2020
Q2 		– Sell
-11,648
Closed -$349K – 1096
2020
Q1 		$349K Sell
11,648
-1,025
-8% -$27.2K 0.08% 313
2019
Q4 		$351K Buy
+12,673
New +$288K 0.04% 480

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

FORA Capital's IOVA Position: Q2 2025 in Review

FORA Capital sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 16,106 shares — an estimated $53.6K sold.

FORA Capital first reported a position in IOVA in Q4 2019 and held it in 5 quarters. The position peaked at $618K in Q4 2020. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • FORA Capital reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • FORA Capital sold 16,106 Iovance Biotherapeutics shares in Q2 2025, an estimated $53.6K.
  • FORA Capital first reported a position in Iovance Biotherapeutics in Q4 2019 and held it in 5 quarters.
  • FORA Capital's Iovance Biotherapeutics position peaked at $618K in Q4 2020.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on FORA Capital's 13F filing for Q2 2025, filed 13 Aug 2025.